Fox Run Management, L.L.C. Edwards Lifesciences Corp Transaction History

Fox Run Management, L.L.C.

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$72.54 - $95.56 $937,652 - $1.24 Million	12,926 New	12,926 $1.24 Million
Q3 2023 Nov 07, 2023	BUY	$69.28 - $93.38 $692,107 - $932,866	9,990 New	9,990 $692,000
Q1 2023 May 12, 2023	SELL	$74.26 - $84.51 $154,238 - $175,527	-2,077 Reduced 26.78%	5,680 $469,000
Q4 2022 Feb 07, 2023	BUY	$68.3 - $87.44 $92,546 - $118,481	1,355 Added 21.17%	7,757 $578,000
Q3 2022 Nov 07, 2022	BUY	$82.37 - $107.29 $527,332 - $686,870	6,402 New	6,402 $529,000
Q2 2022 Aug 12, 2022	SELL	$86.5 - $128.27 $223,689 - $331,706	-2,586 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$101.96 - $128.34 $263,668 - $331,887	2,586 New	2,586 $304,000
Q3 2021 Nov 15, 2021	SELL	$102.91 - $122.75 $319,844 - $381,507	-3,108 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$83.84 - $104.76 $260,574 - $325,594	3,108 New	3,108 $322,000
Q1 2020 May 08, 2020	SELL	$52.41 - $81.0 $85,166 - $131,625	-1,625 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$71.7 - $82.09 $116,512 - $133,396	1,625 New	1,625 $379,000
Q1 2019 Oct 17, 2019	SELL	$47.89 - $64.05 $223,981 - $299,561	-4,677 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$46.41 - $56.94 $137,048 - $168,143	2,953 Added 171.29%	4,677 $716,000
Q3 2018 Oct 05, 2018	SELL	$45.7 - $58.03 $105,795 - $134,339	-2,315 Reduced 57.32%	1,724 $300,000
Q2 2018 Jul 17, 2018	BUY	$42.45 - $51.3 $171,455 - $207,200	4,039 New	4,039 $588,000
Q4 2017 Jan 18, 2018	SELL	$33.79 - $39.39 $452,786 - $527,826	-13,400 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$36.29 - $38.83 $486,286 - $520,322	13,400	13,400 $1.47 Million

1,417

469M

2.44M

2.65M

Ticker EW
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 618,259,968
Market Cap $40.5B
Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.